To cover taxes, Beam Therapeutics (BEAM) treasurer sells 187 shares automatically.
Beam Therapeutics' SVP, Finance and Treasurer, Bethany J. Cavanagh, automatically sold 187 shares of common stock at $24.41 per share on October 1, 2026. This non-discretionary sale was executed under a Rule 10b5-1 plan to cover tax withholding obligations associated with the vesting of restricted stock units. Following the transaction, Cavanagh directly held 50,984 shares.
Beam Therapeutics SVP Bethany Cavanagh Sells 187 Shares to Cover RSU Tax Withholding
Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics Inc., sold 187 shares of the company's common stock on October 1, 2026, for $24.41 per share. This sale was a non-discretionary transaction executed under a Rule 10b5-1 trading plan to cover tax withholding obligations associated with the vesting of restricted stock units. Following the transaction, Cavanagh directly holds 50,984 shares of Beam Therapeutics common stock.
Beam Therapeutics (BEAM) Could Be 52% Undervalued Following Its Lawsuit Over Research Misuse
Beam Therapeutics (BEAM) is facing a lawsuit for alleged misuse of confidential research by a former scientist, which has put the company in the spotlight and seen its stock drop. Despite recent share price declines, a key narrative suggests the stock is 52% undervalued with a fair value of $51.07, driven by promising preclinical results for its lead programs. However, another analysis indicates the company looks expensive based on its sales multiple, trading at 15.6x P/S compared to a sector average of 12.4x and a fair ratio of 0.8x.
Beam says Chinese firm, Serapha stole trade secrets (BEAM)
Beam Therapeutics has filed a lawsuit alleging that Chinese biotech YolTech Therapeutics and its U.S. partner Serapha Bio stole trade secrets. The lawsuit claims that Serapha Bio, which recently merged with Boundless Bio, developed a medicine using these stolen trade secrets.
How Investors May Respond To Beam Therapeutics (BEAM) Trade Secrets Lawsuit
Beam Therapeutics has filed a lawsuit against a former scientist and two companies, alleging theft of trade secrets related to rare disease treatments and gene editing technology. This legal development could impact investor perception of Beam's intellectual property, competitive standing, and legal risks, adding to the company's existing challenges of advancing clinical trials, managing competition, and securing funding amidst ongoing losses. Investors are advised to consider the implications of this lawsuit alongside clinical updates and financial projections.
Beam Therapeutics Inc (NASDAQ: BEAM) Share Price, BEAM Stock News, BEAM Share Price & Updates
Beam Therapeutics Inc. (NASDAQ: BEAM) is a biotechnology company focused on developing precision genetic medicines using base editing technology. The company's pipeline includes treatments for sickle cell disease, alpha-1 antitrypsin deficiency, phenylketonuria, and glycogen storage disease type 1a. Beam Therapeutics has collaborations with Pfizer Inc., Verve Therapeutics, Inc., and Orbital Therapeutics to advance its programs.
Beam sues 2 biotechs, alleging theft of base editing trade secrets
Beam Therapeutics has filed a lawsuit against Chinese biotech YolTech Therapeutics and its U.S. partner Serapha Bio, claiming that an experimental treatment was developed using stolen trade secrets. Beam alleges that a former scientist, Zi Jun “Emma” Wang, secretly founded YolTech while still employed at Beam and filed patent applications based on Beam's confidential information. Serapha Bio, which licensed the therapy from YolTech, denies the allegations.
Beam Therapeutics remains a long-term buy with strong 2028-29 upside from gene editing advances.
Beam Therapeutics is considered a long-term buy due to its leadership in gene editing, particularly with its AATD treatment BEAM-302, which is expected to drive significant growth by 2028-2029. Despite a downgraded potential for Risto-cel, the company's first-mover advantage in base editing and potential AI partnerships strengthen its future prospects. While Beam has a 2-3 year cash runway and may face dilution, its valuation is deemed fair given the pipeline risks and innovation potential.
Beam Therapeutics (BEAM) president gifts shares to a family trust and retains 130,504 directly.
Beam Therapeutics President Giuseppe Ciaramella gifted 123,407 shares of common stock to an irrevocable trust on September 24, 2026. His spouse is the trustee, and his spouse and children are the beneficiaries. Following this transaction, Ciaramella directly holds 130,504 shares and indirectly holds 123,407 shares through the trust, disclaiming beneficial ownership of the trust's securities.
Beam Therapeutics (BEAM) Stock Looks Fully Valued Despite In Vivo Gene Editing Growth
Beam Therapeutics (BEAM) stock appears fully valued despite its role in the growing in vivo gene editing market. The company's P/S ratio of 15.6x is above the biotech industry average, suggesting a premium valuation. While recent research highlights Beam's potential, its current share price embeds high expectations for future sales efficiency, indicating it screens as expensive on a sales basis.
How Positive BEAM 302 Data At Beam Therapeutics (BEAM) Has Changed Its Investment Story
Beam Therapeutics reported positive Phase 1/2 data for BEAM-302, its treatment for alpha-1 antitrypsin deficiency, showing good tolerability and sustained AAT levels. This success, coupled with the plan to pursue accelerated FDA approval, could significantly alter investor perception of Beam's genetic medicine pipeline. The data reinforces the potential of its base editing platform and shifts the investment narrative towards real-world clinical progress, moving beyond just preclinical promise.
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
Schall, Brown & Schwartz LLP (SBS) has initiated an investigation into Beam Therapeutics Inc. (NASDAQ: BEAM) on behalf of investors for potential securities law violations. The investigation follows a 9.5% drop in Beam's share price after the company disclosed updated clinical data for BEAM-302, which, despite being well tolerated, showed "transient and predominantly Grade 1 alanine transaminase (ALT) and/or aspartate aminotransferase (AST) elevations." SBS is encouraging affected shareholders to join the fraud investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAM
Pomerantz LLP is investigating potential securities fraud claims against Beam Therapeutics Inc. (NASDAQ: BEAM) on behalf of its investors. This investigation follows a 9.54% drop in Beam's stock price after the company announced updated clinical data for BEAM-302, which, despite being well-tolerated, showed transient liver enzyme elevations. Investors who experienced losses are encouraged to contact the law firm to learn about joining a potential class action lawsuit.
Cathie Wood’s ARK sells Alphabet stock, buys Meta and Beam Therapeutics
Cathie Wood's ARK Investment Management recently divested 84,392 shares of Alphabet (GOOGL) totaling $28.55 million across its ARKK and ARKW ETFs. Simultaneously, ARK made significant purchases, acquiring 43,091 shares of Meta Platforms (META) worth $26.44 million and 271,159 shares of Beam Therapeutics (BEAM) valued at $7.28 million, indicating a strategic shift towards social media and biotechnology. These trades highlight ARK's dynamic portfolio management, actively rebalancing holdings in response to market conditions and investment strategies.
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics announced updated clinical data from its Phase 1/2 trial of BEAM-302 for alpha-1 antitrypsin deficiency (AATD), presented at the European Respiratory Society Congress 2026. The data show that BEAM-302, a one-time gene-editing treatment, continues to demonstrate potential for addressing both lung and liver manifestations of AATD by restoring functional AAT levels and reducing mutant Z-AAT. The company plans to pursue an accelerated approval pathway with the FDA and has begun dosing patients in a global pivotal cohort.
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics announced updated clinical data from its Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency (AATD) at the ERS Congress 2026. The data showed that a single dose of BEAM-302 led to rapid and durable increases in total and functional AAT, decreased mutant Z-AAT and toxic Z-polymers, and produced corrected M-AAT, with AAT levels remaining under physiological control. The company is pursuing an accelerated approval pathway for BEAM-302 based on these promising results, with dosing underway in a global pivotal cohort.
Beam Therapeutics (BEAM) Earnings History & Trends
This article provides an overview of Beam Therapeutics (BEAM) earnings history and trends, including EPS and revenue compared to Street estimates. It highlights a 50% EPS beat rate and a 51.61% average EPS surprise. The report also details quarterly performance, showing both estimated and actual EPS and revenue figures, along with surprise percentages for recent quarters.
Beam Therapeutics names Eric Foster as chief commercial officer By Investing.com
Beam Therapeutics Inc. (NASDAQ:BEAM) has announced the appointment of Eric Foster as its new chief commercial officer. Foster, who brings over 25 years of commercial leadership experience, will be responsible for leading the company's commercial organization and strategy, particularly as Beam prepares for potential product launches, including risto-cel in 2027. His previous roles include chief commercial officer at Ardelyx and senior leadership positions at Amgen and Horizon Therapeutics.
Beam Therapeutics names Eric Foster as chief commercial officer
Beam Therapeutics (NASDAQ:BEAM) has appointed Eric Foster as its new chief commercial officer. Foster brings over 25 years of experience in biotechnology and specialty pharmaceuticals, having held leadership roles at Ardelyx, Amgen, Horizon Therapeutics, GlaxoSmithKline, and Johnson & Johnson. He will be responsible for leading the company's commercial organization and strategy, particularly as Beam prepares for a potential 2027 launch of its product candidate, risto-cel.
Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Beam Therapeutics announced its participation in three investor conferences in September 2026: the Wells Fargo 21st Annual Healthcare Conference, Citi’s Biopharma Back to School Conference, and the Cantor Fitzgerald Global Healthcare Conference 2026. Management will participate in fireside chats, with webcasts available on the company's website. The company specializes in precision genetic medicines using base editing technology.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reaffirmed its Buy rating and $80.00 price target for Beam Therapeutics (NASDAQ: BEAM), noting the company's strong cash position and pipeline progress. Despite the stock trading above its Fair Value according to InvestingPro data, the firm highlighted advancements in BEAM-302, risto-cel, and FDA clearance for BEAM-304. Beam Therapeutics reported $1.15 billion in cash as of June 30, providing a runway into mid-2029.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reiterated a Buy rating and an $80.00 price target for Beam Therapeutics Inc (NASDAQ:BEAM), following a 72% stock return over the past year. The firm highlighted progress on key clinical programs including BEAM-302 for AATD, risto-cel for sickle cell disease, and BEAM-304 for phenylketonuria, with a biologics license application for risto-cel on track for year-end 2026. Beam Therapeutics reported $1.15 billion in cash as of June 30, with a runway into mid-2029, though analysts do not anticipate profitability this year.
Beam Therapeutics (NASDAQ:BEAM) Stock Price Down 6.2% - Here's What Happened
Beam Therapeutics (NASDAQ:BEAM) saw its stock price drop 6.2% to $27.26 following a significant earnings miss. The company reported an EPS loss of $1.18 against an expected $1.11 loss, and revenue of $0.49 million, far below estimates of $16.37 million, marking a 94.2% year-over-year decline. Despite the poor financial results, analyst sentiment remains a "Moderate Buy" with an average price target of $49.00.
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Up - Should You Buy?
Beam Therapeutics (NASDAQ:BEAM) shares gapped up 4.6% to $28.41, opening higher than its previous close of $26.57, despite reporting weaker-than-expected quarterly results with a significant revenue drop and a larger-than-anticipated loss per share. Analysts hold a "Moderate Buy" rating with a $49 price target, although company insiders have sold a substantial amount of shares recently. Institutional investors, however, maintain a strong ownership of 99.68% in the company.
Alphabet Inc. Purchases New Shares in Beam Therapeutics Inc. $BEAM
Alphabet Inc. has acquired a new stake in Beam Therapeutics Inc. (NASDAQ:BEAM) during the second quarter, purchasing 321,604 shares valued at approximately $11.0 million, representing 0.31% ownership. Despite this institutional investment, Beam Therapeutics reported a quarterly loss and significant revenue decline, missing analyst estimates. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average price target of $49.00, though recent insider selling has also been noted.
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Beam Therapeutics Inc. (NASDAQ:BEAM) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $49.00. Despite this positive outlook, the company recently reported a quarterly loss of $1.18 per share, missing estimates, and revenue of $0.49 million, significantly below expectations and down 94.2% year-over-year. Insiders sold $10.5 million worth of stock, while institutional investors hold 99.68% of shares.
Beam Therapeutics (BEAM): ARK Investment and Cathie Wood report 9.95% stake
ARK Investment Management LLC and Cathie Wood have reported a beneficial ownership of 9.95% in Beam Therapeutics Inc. (BEAM), totaling 10,234,862 shares. This disclosure, filed via a SCHEDULE 13G/A, indicates that ARK has significant voting and dispositive power over these shares. The filing also notes that the ARK Innovation ETF is the only client with more than a 5% interest in these securities.
Farallon funds report 10.28M-share, 9.99% Beam Therapeutics (BEAM) position
Farallon Capital Management and its affiliated funds have disclosed a beneficial ownership of 10,282,210 shares of Beam Therapeutics (BEAM) common stock, representing 9.99% of the outstanding class. This position includes directly held shares and common stock purchase warrants, with exercisability capped at 9.99% due to a beneficial ownership limitation. The filing details the ownership structure and key figures of this significant investment.
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM)
Analysts have issued a major negative revision to Beam Therapeutics Inc.'s near-term revenue forecasts for 2026, anticipating a significant decline in sales while losses per share are expected to balloon. Despite the drastic revenue downgrade, the consensus price target remains unchanged, suggesting analysts do not foresee a long-term impact on the company's valuation. However, the company's projected revenue decline of 90% by 2026 indicates it will lag behind the broader industry's growth.
Weekly Recap: H1 2026 financials and BEAM-302 pivotal cohort dosing
Beam Therapeutics (NASDAQ:BEAM) reported its H1 2026 financials, including $32.2M in revenue and a $217M net loss, with a cash position of ~$1.15B, extending its runway into mid-2029. The company also announced it has dosed the first patient in the pivotal global cohort for BEAM-302, targeting alpha-1 antitrypsin deficiency, moving towards potential accelerated U.S. approval.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reiterated its Buy rating and an $80.00 price target for Beam Therapeutics Inc. (NASDAQ:BEAM), indicating a 64% potential upside. This endorsement follows Beam's positive clinical developments, including dosing the first patient in a pivotal trial for BEAM-302 and progress on other gene-editing therapies, despite a recent arbitration ruling against them concerning development rights for PM647.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy By Investing.com
H.C. Wainwright has reiterated a Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM) with an $80.00 price target, suggesting a 64% upside. The company recently reported progress on its clinical trials for BEAM-302, BEACON, and BEAM-304, and is expecting updated data and regulatory submissions by year-end 2026. Despite a collaboration dispute ruling with Prime Medicine, other analysts maintain positive ratings, noting the specific nature of the ruling.
Analyst Forecasts Just Became More Bearish On Beam Therapeutics Inc. (NASDAQ:BEAM)
Analysts have significantly downgraded their near-term revenue forecasts for Beam Therapeutics Inc. (NASDAQ:BEAM), now expecting a 69% decline in sales for 2026, though loss per share estimates remain steady. Despite the bearish revenue outlook, the consensus price target of US$52.15 remains unchanged, suggesting analysts do not anticipate a long-term impact on valuation. The company's projected revenue decline is also expected to significantly lag the broader biotech industry.
H.C. Wainwright reiterates Beam Therapeutics stock rating at buy
H.C. Wainwright has reiterated a Buy rating and an $80.00 price target for Beam Therapeutics Inc. (NASDAQ:BEAM), representing a 64% potential upside. The company is advancing several clinical programs, including BEAM-302 for AATD-associated lung disease, ristoglogene autogetemcel (risto-cel) with a biologics license application expected by year-end 2026, and BEAM-304 for phenylketonuria. Despite a recent arbitration ruling in favor of Prime Medicine regarding development rights for PM647, analysts maintain a positive outlook on Beam Therapeutics' pipeline and manufacturing capabilities.
(BEAM) and the Role of Price-Sensitive Allocations
This article analyzes Beam Therapeutics Inc. (NASDAQ: BEAM), highlighting a mid-channel oscillation pattern and an exceptional 62.6:1 risk-reward setup. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and time horizons. The analysis suggests a near-term strong sentiment, mid-term neutrality, and long-term positive bias for the stock.
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results
Analysts have lowered their revenue expectations for Beam Therapeutics Inc. (NASDAQ:BEAM) after the company reported second-quarter results that fell significantly short of estimates, with revenues missing by 97% and losses being higher than modeled. Despite the substantial haircut to revenue forecasts for 2026, the average price target for BEAM has remained largely unchanged, indicating analysts believe the long-term intrinsic value is unaffected. The company's revenues are now projected to decline significantly by 2026, performing much worse than the broader industry.
Analysts Have Lowered Expectations For Beam Therapeutics Inc. (NASDAQ:BEAM) After Its Latest Results
Analysts have lowered their revenue expectations for Beam Therapeutics (NASDAQ:BEAM) after the company reported second-quarter results that fell short of estimates. While revenue forecasts for 2026 were significantly cut, loss per share estimates remained steady, and the average price target did not change, suggesting analysts don't foresee a long-term impact on valuation despite the short-term disappointment. The company's revenue is now expected to decline significantly, underperforming the broader biotech industry.
Beam Therapeutics Number of Employees 2026 | Employee Count & Headcount Data
Beam Therapeutics, Inc. (NASDAQ: BEAM) had approximately 517 employees worldwide as of March 2026, marking a 2.3% decline from 530 employees in 2023. Despite this overall decline, the company is actively hiring, with 71 active job postings in 2026, a 42.7% increase from 2025. The workforce is primarily concentrated in North America, with an average salary of $184,848.
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
Beam Therapeutics (BEAM) reported a wider-than-expected loss of $1.18 per share in Q2 2026, missing the Zacks Consensus Estimate of a $1.00 loss, and revenues fell significantly year-over-year. Despite the financial performance, the company is advancing its pipeline, including candidates for sickle cell disease (risto-cel), glycogen storage disease type Ia (BEAM-301), alpha-1 antitrypsin deficiency (BEAM-302), and phenylketonuria (BEAM-304), with several clinical data readouts and regulatory filings anticipated. The company maintains a strong cash position, expected to fund operations into mid-2029.
How Beam’s Wider Q2 Loss and Trial Progress Will Impact Beam Therapeutics (BEAM) Investors
Beam Therapeutics reported a wider net loss of US$122.68 million and a revenue shortfall in Q2 2026, yet achieved key clinical milestones including completing dosing for its risto-cel sickle cell trial and dosing the first patient in the BEAM-302 study. The article discusses how these developments, particularly the progress toward a risto-cel BLA filing, shape the company's investment outlook despite ongoing financial losses and potential risks related to conditioning regimens. Beam's investment narrative projects significant revenue and earnings growth by 2029, suggesting a potential 89% upside to its current price according to Simply Wall St's fair value analysis.
Beam Therapeutics Inc. Stock 12‑Month Price Target Cut to $51.07, Implies 80% Upside
Analysts have cut the average 12-month price target for Beam Therapeutics Inc. (BEAM) stock from $51.36 to $51.07, with individual forecasts ranging from $26 to $80 per share. This updated target suggests an 80% potential upside based on the Aug. 4 closing price. The consensus rating from 16 analysts remains a "Buy," with 14 Buys, 2 Holds, and 0 Sells.
Beam Therapeutics (BEAM) On A Wider Q2 Loss And The Valuation Debate
Beam Therapeutics (BEAM) reported a wider net loss and higher loss per share for Q2 2026, yet saw a short-term share price bounce. Despite a challenging longer-term stock performance, a "Most Popular Narrative" suggests the company is 44.5% undervalued with a fair value of $51.07, driven by expectations for its ESCAPE technology. However, this bullish outlook depends on managing safety concerns and securing funding, and a simpler P/S ratio cross-check raises valuation risks.
Beam Therapeutics completes dosing in sickle cell trial
Beam Therapeutics announced the completion of dosing for adult and adolescent patients in its Phase 1/2 BEACON trial for sickle cell disease, with a biologics license application expected by late 2026 and updated data by year-end. The company also reported progress in other trials, including BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-304 for phenylketonuria, and detailed its financial position with $1.2 billion in cash and equivalents.
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) reported a Q2 loss of $1.18 per share, missing the Zacks Consensus Estimate of a $1 loss and underperforming the previous year's loss of $1 per share. The company's revenues for the quarter were $0.49 million, significantly below the Zacks Consensus Estimate of $30.33 million and down from $8.47 million a year ago. Despite underperforming the S&P 500 year-to-date, the stock currently holds a Zacks Rank #3 (Hold), indicating an expected in-line performance with the market.
Beam Therapeutics Inc. 2Q 2026: Revenue $0.5M, EPS $(1.18) — 10-Q Summary
Beam Therapeutics Inc. reported its second-quarter 2026 results, showing a revenue of $0.5 million and a diluted loss per share of $(1.18). The company also highlighted clinical progress with its BEACON risto-cel program targeting a BLA filing by year-end 2026, advancing LNP programs, and ongoing strategic collaborations. A new 100k sq ft cGMP facility is now online to support both ex vivo and in vivo programs.
Earnings Flash (BEAM) Beam Therapeutics Inc. Reports Q2 Revenue $490,000, vs. FactSet Est of $16.4M
Beam Therapeutics Inc. reported Q2 revenue of $490,000, significantly missing the FactSet estimate of $16.4 million. The company also posted a Q2 loss of $1.18 per share, which was higher than the FactSet estimated loss of $1.11 per share. This financial update indicates a challenging quarter for the biotechnology firm.
Beam Therapeutics (NASDAQ: BEAM) details Q2 loss, $1.2B cash and pipeline plans
Beam Therapeutics reported a Q2 2026 net loss of $122.7 million ($1.18 per share) on $490 thousand in license and collaboration revenue, ending the quarter with $1.2 billion in cash. The company expects this capital, plus an additional $200 million from a credit facility, to fund operations into mid-2029. Beam highlighted significant clinical progress, including dosing the first patient in the pivotal BEAM-302 AATD trial, completing dosing in the BEACON risto-cel SCD trial with a BLA submission anticipated by year-end 2026, and FDA clearance of the IND for BEAM-304 in PKU.
Beam Therapeutics Inc (BEAM) Institutional Confidence
Beam Therapeutics Inc (BEAM) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding stands at 103.20%, a decrease of 9.85% quarter-over-quarter. Catherine Wood is the largest institutional shareholder, holding 9.07 million shares, which represents 12.21% of outstanding shares.
Beam Therapeutics Inc (BEAM) Financial Health: Profitability & Balance Sheet Analysis
Beam Therapeutics Inc.'s (BEAM) financial score is 7.49, indicating a stable financial status but low operating efficiency within the Biotechnology & Medical Research industry. The company reported a 324.87% year-over-year revenue increase to $31.74M and a 13.68% increase in net profit. The analysis provides scores across various financial dimensions like Quality of Earnings and Growth Potential, noting that relevant data for some metrics have not yet been disclosed by the company.
Beam Therapeutics (BEAM) CMO sells 16,667 shares under 10b5-1 plan
Beam Therapeutics' Chief Medical Officer, Simon Amy, sold 16,667 shares of common stock on July 27, 2026, at a weighted average price of $25.7417 per share. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2026. Following the transactions, Amy directly holds 85,696 shares of Beam Therapeutics common stock.
